8:00-8:30 |
Registration and Coffee |
8:30-9:15 |
State of the Neurotechnology Industry: 2019 James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occured over the years, the most significant events of the last year, and challenges confronting the industry in years ahead. |
9:15-10:00 |
Keynote Address
Josh Makower, M.D., General Partner, New Enterprise Associates |
10:00-10:30 |
Refreshment Break |
10:30-11:15 |
Finding the Money: The Outlook for Neurotech Investment
James Childs, Parnter, Maynard Cooper & Gale, Moderator
Mike Edelhart, Managing Partner, Joyance Partners
John Kim, M.D., Principal, Aphelion Capital
Stephanie Fertig, SBIR Project Manager, National Institutes of Health/NINDS
Several neurotech firms have have had successful IPO exits in the last few years, and serval others have been acquired by larger healthcare firms. What does all this market activity mean for neurotech startups in 2019? Key VCs and industry executives will weigh in. |
11:15-12:00 |
Trials and Tribulations: Addressing Issues with Neuromodulation Studies
James Cavuoto, Editor, Neurotech Reports, Moderator
Robert Greenberg, M.D., Ph.D., Chairman, Alfred Mann Foundation
Jonathan Sackier, M.D., CMO, Helius Medical Technologies
Jim Hamer, Senior Clinical Project Manager, DP Clinical
Pivotal trials can either make or break a neuromodulation firm. In this session, we'll examine several recent clinical trial failures and discuss strategies for designing a successful trial. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical
Brian Highley, CEO, Cirtec Medical |
1:30-3:00 |
Neurotechnology Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Ingrid van Welie, Ph.D., Founder and CEO, Neural Dynamics Technologies LLC
Claire Dixon, COO, Neuraura Biotech Inc.
Philip Kennedy, Ph.D., M.D., CEO, Neural Signals Inc.
Dan Rizzuto, Ph.D., CEO, Nia Therapeutics
Owen Philips, Ph.D., Co-founder and CEO, BrainKey
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Choosing our Pain: Navigating the Spinal Cord Stimulation Landscape
Jeremy Koff, Senior Contributing Editor, Neurotech Reports, Moderator
Lawrence Poree, M.D., Ph.D., Professor of Anesthesia, UCSF School of Medicine
Erika Ross, Ph.D., Director, Applied R&D, Abbott Neuromodulation
Nick Langhals, Ph.D., Neural Engineering Program Manager, NIH NINDS
The market for spinal cord stimulation has grown more complex and diversified in recent years. In this session, clinicians and industry experts will discuss the numerous options available to patients suffering from chronic pain. |
4:15-5:00 |
Found in Translation: Neurotech Moves from Lab to Market
Jennifer French, Senior Editor, Neurotech Reports, Moderator
Jacob Zabara, Ph.D., President, Jacob Zabara Family Foundation
Gordon Saul, Executive Director, Stanford Byers Center for Biodesign
Chris Czura, Ph.D., Co-founder and CSO, Convergent Medical Technologies
In recent years, we've seen several successful neurotech startups emerge from university or private foundation research labs. In this session, we'll take a look at new therapies and devices that may emerge in coming years.
|
5:00-7:00 |
Cocktail Reception, Sponsored by MST
|
|
|
8:00:8:30 |
Registration and Coffee |
8:30-9:15 |
Facing the Public: An Editorial Perspective
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Jennifer French, Senior Editor, Neurotech Reports
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Margot Puerta, Contributing Editor, Neurotech Reports
In this session, Neurotech Reports team of editors will offer their views on recent controversies facing the neuromodulation industry, including ethical concerns, dealing with bad press, and legislative and regulatory developments.
|
9:15-10:00 |
Keynote Address
Robert Knight, M.D., Professor of Psychology and Neuroscience, University of California, Berkeley
|
10:00-10:30 |
Coffee Break
|
10:30-11:15 |
Coming to the Surface: The Noninvasive Neuromodulation Market Expands
Jeremy Koff, Senior Contributing Editor, Neurotech Reports, Moderator
Daniel Powell, CEO, Spark Biomedical
Jennifer Ernst, CEO, Tivic Health
Daniel Chao, M.D., Co-founder, Halo Neuroscience
Once thought of as snake-oil, noninvasive neuromodulation therapies have rapidly gained a foothold in the medical device and consumer wellness markets. In this session, we'll look at several examples and examine their position vis a vis implanted devices.
|
11:15-12:00 |
Closing the Loop: The Role of Neurosensing in New Therapies
James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Dan Brounstein, Vice-President, Saluda Medical
Ana Maiques, CEO, Neuroelectrics Corp.
Kewal Jain, M.D., President, Jain PharmaBiotech
Neurosensing devices have come to play a key role in developing new closed-loop neuromodulation therapies. In this session, we'll examine key technologies like brain-computer interfaces, EEG interpretation software, and peripheral nerve and muscles sensors. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical
Presentation of 2019 Gold Electrode Awards |
1:30-3:00 |
Neurotechnology Entrepreneur Panel
James Cavuoto, Editor, Neurotech Reports, Moderator
Emil Hewage, Ph.D., Co-Founder and CEO, BIOS
Stephen Popielarski, Ph.D., CEO, Thermaquil
Chris Castel, Ph.D., CEO, CareWear Corp.
Brian Pepin, CEO, Rune Labs
Iain Cameron McIntyre, CEO and Co-founder, Humm
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Out on a Limb: New Strategies for Restoring Function
Jennifer French, Senior Editor, Neurotech Reports, Moderator
Asgeir Alexandersson, M.D., Director of Research & Innovation, Ossur
Maura Whittaker, Founder, FES Mobility Ltd.
Marcus Gerhardt, CEO, Blackrock Microsystems
Several new neuroprosthetics and neurorehabilitation therapies have emerge recently to treat neurological disorders like spinal cord injury, traumatic brain injury, and stroke. In this session, we'll look at some innovative--if unconventional--approaches to restoring upper and lower extremity function. |
4:15-5:00 |
Finding the Target: The Hunt for New Indications and Therapies
Margot Puerta, Contributing Editor, Neurotech Reports, Moderator
Avery Bedows, Neurotech Investor, Loup Ventures
Paul Meadows, Ph.D., Principal, Paul Meadows Consulting
Elliot Krames, M.D., Past President, International Neuromodulation Society
Neurotech entrepreneurs and investigators have discovered many new potential targets of neurostimulation to treat a wide range of disorders in recent years. In this closing session, we'll take a look at some of the most promising future applications of bioelectronic medicine, and the stimulation paradigms employed in the new therapies. |
5:00-7:00 |
Cocktail Reception, Sponsored by MST |
|
|
